We are live on
!
Find out more
GT
Glenmede Trust Portfolio holdings
AUM
$20.4B
This Fund
S&P 500
This Quarter
Est. Return
+2.37%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$10.8B
AUM Growth
+$988M
(+10%)
Cap. Flow
+$812M
Cap. Flow
% of AUM
7.54%
Top 10 Holdings %
Top 10 Hldgs %
14.36%
Holding
2,596
New
200
Increased
685
Reduced
635
Closed
273
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vanguard FTSE All-World ex-US ETF
VEU
|
+$32.7M |
| 2 |
Eli Lilly
LLY
|
+$31M |
| 3 |
La-Z-Boy
LZB
|
+$17.4M |
| 4 |
Ubiquiti
UI
|
+$17.1M |
| 5 |
TriMas Corp
TRS
|
+$16.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
LSB Industries
LXU
|
+$14M |
| 2 |
K
Kellanova
K
|
+$13.7M |
| 3 |
Apple
AAPL
|
+$13.1M |
| 4 |
Prosperity Bancshares
PB
|
+$11.7M |
| 5 |
Fluor
FLR
|
+$11.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 13.72% |
| 2 | Industrials | 12.7% |
| 3 | Healthcare | 12.22% |
| 4 | Financials | 10.93% |
| 5 | Energy | 9.3% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
MRSH
251
Marsh
MRSH
$86.3B
| $11.9M | 0.11% |
241,593
+15,305
| +7% | +$733K |
|
252
Gilead Sciences
GILD
$161B
| $11.8M | 0.11% |
166,695
+40,830
| +32% | +$3.2M |
|
253
Mastercard
MA
$477B
| $11.8M | 0.11% |
157,655
+121,725
| +339% | +$9.51M |
|
|
RDS.A
254
DELISTED
Royal Dutch Shell PLC ADS Class A
RDS.A
| $11.7M | 0.11% |
160,351
-20,617
| -11% | -$1.47M |
|
255
McKesson
MCK
$98.5B
| $11.6M | 0.11% |
65,576
-14,072
| -18% | -$2.46M |
|
|
CGI
256
DELISTED
Celadon Group Inc
CGI
| $11.4M | 0.11% |
475,322
+79,158
| +20% | +$1.72M |
|
257
Booking.com
BKNG
$138B
| $11.2M | 0.1% |
235,950
+2,175
| +0.9% | +$107K |
|
258
iShares Core S&P Small-Cap ETF
IJR
$109B
| $11.2M | 0.1% |
202,616
-666
| -0.3% | -$36K |
|
259
General Dynamics
GD
$105B
| $11.1M | 0.1% |
102,136
+70,742
| +225% | +$7.33M |
|
260
Phillips 66
PSX
$82.9B
| $11.1M | 0.1% |
143,558
-5,249
| -4% | -$400K |
|
|
RPXC
261
DELISTED
RPX Corporation
RPXC
| $11.1M | 0.1% |
679,038
+112,017
| +20% | +$1.83M |
|
262
Bath & Body Works
BBWI
$4.01B
| $11M | 0.1% |
239,376
+4,945
| +2% | +$223K |
|
|
STI
263
DELISTED
SunTrust Banks, Inc.
STI
| $11M | 0.1% |
275,531
+111,897
| +68% | +$4.28M |
|
264
iShares Russell 3000 ETF
IWV
$19.5B
| $10.9M | 0.1% |
97,463
-22,491
| -19% | -$2.48M |
|
265
WesBanco
WSBC
$3.95B
| $10.9M | 0.1% |
343,926
+57,421
| +20% | +$1.71M |
|
266
Viatris
VTRS
$20.1B
| $10.9M | 0.1% |
223,569
+3,733
| +2% | +$181K |
|
267
LyondellBasell Industries
LYB
$19.5B
| $10.8M | 0.1% |
121,112
-12,137
| -9% | -$1.02M |
|
268
Invesco
IVZ
$13.3B
| $10.6M | 0.1% |
286,976
-56,615
| -16% | -$1.96M |
|
269
Travel + Leisure Co
TNL
$4.54B
| $10.5M | 0.1% |
317,582
+2,870
| +0.9% | +$93.7K |
|
270
Emergent Biosolutions
EBS
$375M
| $10.5M | 0.1% |
+414,923
| New | +$10.5M |
|
|
AVTA
271
DELISTED
Avantax, Inc. Common Stock
AVTA
| $10.4M | 0.1% |
529,941
+87,234
| +20% | +$2.02M |
|
272
Thermo Fisher Scientific
TMO
$211B
| $10.4M | 0.1% |
86,736
-6,936
| -7% | -$825K |
|
|
TCF
273
DELISTED
TCF Financial Corporation Common Stock
TCF
| $10.4M | 0.1% |
320,876
+52,730
| +20% | +$1.61M |
|
|
KS
274
DELISTED
KapStone Paper and Pack Corp.
KS
| $10.4M | 0.1% |
360,432
+60,280
| +20% | +$1.76M |
|
|
SIMG
275
DELISTED
SILICON IMAGE INC
SIMG
| $10.4M | 0.1% |
1,504,592
+1,439,777
| +2,221% | +$8.87M |
|
Similar funds
SLAM
EWA
MIC
P
OSAM
CB
EIM
Glenmede Trust's Q1 2014 Portfolio in Review
As of Q1 2014, Glenmede Trust held 2,596 positions worth $10.8B, up 10% from $9.79B the previous quarter. Its ten largest holdings account for 14% of the portfolio.
Glenmede Trust deployed $812M of net new capital in Q1 2014, opening 200 new positions and adding to 685 existing holdings. Its largest new stake was Vanguard FTSE All-World ex-US ETF: 661,076 shares worth $33.3M.
By sector, the portfolio is most concentrated in Technology at 14% of assets, down from 14% a quarter earlier, followed by Industrials and Healthcare.
On the sell side, the largest reduction was Kellanova, an estimated $13.7M trimmed.
- Glenmede Trust's largest Q1 2014 buy was Vanguard FTSE All-World ex-US ETF: 661,076 shares worth $33.3M.
- Glenmede Trust added most to Eli Lilly in Q1 2014, an estimated $31M increase.
- Glenmede Trust's biggest Q1 2014 reduction was Kellanova, cutting an estimated $13.7M.
- Glenmede Trust fully exited LSB Industries in Q1 2014, selling an estimated $14M.
- Glenmede Trust's ten largest holdings make up 14% of its $10.8B portfolio in Q1 2014.
- Glenmede Trust opened 200 new positions and closed 273 in Q1 2014.
- Glenmede Trust's portfolio value rose 10% quarter-over-quarter to $10.8B.
Based on Glenmede Trust's 13F filing for Q1 2014, filed 7 May 2014.